Ergoloid Mesylates
FDA-approved product (tablet, sublingual), marketed as Alkergot, Circanol, Deapril-St and 5 more.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Ergot alkaloids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ergoloid Mesylates with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm95.6% AI-predicted activityagainst MRSALab records exist50+ registered studies
- TaurursodiolExisting use: Bile acids and derivatives79.6% AI-predicted activityagainst MRSA43 registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome74.5% AI-predicted activityagainst MRSA50+ registered studies
- PlecanatideExisting use: Constipation74.4% AI-predicted activityagainst MRSA15 registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia74.2% AI-predicted activityagainst MRSA50+ registered studies
- PosaconazoleExisting use: Aspergillosis, Candidiasis, Coccidioidomycosis and 2 more72.2% AI-predicted activityagainst MRSA50+ registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma70.6% AI-predicted activityagainst MRSA50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more70.1% AI-predicted activityagainst MRSA50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia70.0% AI-predicted activityagainst MRSA4 registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more70.0% AI-predicted activityagainst MRSA50+ registered studies
- Deoxycholic AcidExisting use: Other dermatologicals69.3% AI-predicted activityagainst MRSA50+ registered studies
- ChenodiolExisting use: Cerebrotendinous xanthomatosis, Inborn errors of metabolism69.2% AI-predicted activityagainst MRSA30 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
ERG/5-HTP in Fragile X Syndrome (FXS)
NCT05030129 · start 2021-10-07
Registered record
- Registry ID
- NCT05030129
- Conditions
- Fragile X Syndrome
- Interventions
- 5-Hydroxytryptophan; Ergoloid Mesylates; Matching placebo for Ergoloid mesylates; Matching placebo for 5-Hydroxytryptophan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-10-07
- Completion
- 2023-01-19
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFragile X SyndromeIntervention5-Hydroxytryptophan; Ergoloid Mesylates; Matching placebo for Ergoloid mesylates; Matching placebo for 5-HydroxytryptophanPhasePhase 2Registry statusCompletedStudy of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)
NCT01475578 · start 2002-03
Registered record
- Registry ID
- NCT01475578
- Conditions
- Vascular Dementia
- Interventions
- STA-1; Ergoloid Mesylates tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-03
- Completion
- 2002-10
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVascular DementiaInterventionSTA-1; Ergoloid Mesylates tabletPhasePhase 2Registry statusCompleted